Evidence map›Paper›PMID 31384135›Full record

ReviewClinical Medicine Insights. Cardiology2019

Cancer Therapy-Related Cardiac Dysfunction: An Overview for the Clinician.

Irving E Perez, Sara Taveras Alam, Gabriel A Hernandez, Rhea Sancassani

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Clinical Medicine Insights. Cardiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 120 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
120citing papers in PubMed, 5 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

120 citing papers in PubMed, 5 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Cardiac Manifestations ofHealth science reports · 2026
    Review
  14. Article
  15. Review
  16. Diabetes and cancer: therapeutic implications.Cardio-oncology (London, England) · 2026
    Review
  17. Signaling pathways and potential therapeutic agents in trastuzumab-induced cardiotoxicity.Apoptosis : an international journal on programmed cell death · 2026
    Review
  18. Article
  19. Article
  20. Article

60 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Irving E PerezDepartment of Cardiovascular Disease, Jackson Memorial Hospital, University of Miami Hospital, Miami, FL, USA.ORCID https://orcid.org/0000-0002-5594-6237
Sara Taveras AlamSection of Hematology-Oncology, Department of Medicine, Baylor College of Medicine, Houston, TX, USA.
Gabriel A HernandezDepartment of Cardiovascular Disease, Jackson Memorial Hospital, University of Miami Hospital, Miami, FL, USA.
Rhea SancassaniDepartment of Cardiovascular Disease, Jackson Memorial Hospital, University of Miami Hospital, Miami, FL, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer therapy-related cardiac dysfunction (CTRCD) is one of the most feared and undesirable side effects of chemotherapy, occurring in approximately 10% of the patients. It can be classified as direct (dose-dependent vs dose-independent) or indirect, either case being potentially permanent or reversible. Risk assessment, recognition, and prevention of CTRCD are crucial.

Indexed as

cardiac dysfunctioncardio-oncologyCardiotoxicityheart failure

Identifiers

PMID31384135
PMCPMC6664629

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.